ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
67,621.40
0.21%
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs Yen
157.2625
0.01%
Brent Oil
81.295
0.00%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Outlook Therapeutics Inc (OTLK)

  7. Outlook Therapeutics Inc (OTLK) ニュース

OTLK

Outlook Therapeutics (OTLK)

Outlook Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:OTLK
日付受信時刻ニュースソース見出しコード企業名
2024/05/2821 : 05GlobeNewswire Inc.Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDNASDAQ:OTLKOutlook Therapeutics Inc
2024/05/1606 : 19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OTLKOutlook Therapeutics Inc
2024/05/1606 : 15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OTLKOutlook Therapeutics Inc
2024/05/1606 : 00GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKOutlook Therapeutics Inc
2024/05/1405 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OTLKOutlook Therapeutics Inc
2024/05/1321 : 50GlobeNewswire Inc.Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKOutlook Therapeutics Inc
2024/05/0921 : 45GlobeNewswire Inc.Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastNASDAQ:OTLKOutlook Therapeutics Inc
2024/05/0713 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OTLKOutlook Therapeutics Inc
2024/05/0705 : 09Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OTLKOutlook Therapeutics Inc
2024/05/0222 : 05GlobeNewswire Inc.Outlook Therapeutics® to Present at the Retina World Congress 2024NASDAQ:OTLKOutlook Therapeutics Inc
2024/04/2922 : 00GlobeNewswire Inc.Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseNASDAQ:OTLKOutlook Therapeutics Inc
2024/04/1605 : 15GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionNASDAQ:OTLKOutlook Therapeutics Inc
2024/03/2220 : 35GlobeNewswire Inc.Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKOutlook Therapeutics Inc
2024/03/1906 : 10GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of up to $159 MillionNASDAQ:OTLKOutlook Therapeutics Inc
2024/03/1221 : 05GlobeNewswire Inc.Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock SplitNASDAQ:OTLKOutlook Therapeutics Inc
2024/03/1205 : 43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
2024/03/0906 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
2024/03/0906 : 18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
2024/03/0906 : 11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
2024/03/0906 : 08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
2024/03/0806 : 16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OTLKOutlook Therapeutics Inc
2024/02/1507 : 10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OTLKOutlook Therapeutics Inc
2024/02/1506 : 40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OTLKOutlook Therapeutics Inc
2024/02/1422 : 05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKOutlook Therapeutics Inc
2024/02/0821 : 00Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:OTLKOutlook Therapeutics Inc
2024/02/0820 : 59Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:OTLKOutlook Therapeutics Inc
2024/02/0106 : 01Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:OTLKOutlook Therapeutics Inc
2024/01/3122 : 05GlobeNewswire Inc.Outlook Therapeutics® Doses First Subject in NORSE EIGHTNASDAQ:OTLKOutlook Therapeutics Inc
2024/01/3007 : 00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:OTLKOutlook Therapeutics Inc
2024/01/2507 : 00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:OTLKOutlook Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:OTLK

最近閲覧した銘柄

USOTC
ERYFF
PHAXIAM Therapeutics (PK)
LSE
4BB
4basebio
COIN
NYANETH
LSE
2NFL
Ls 2x Netflix
EU
C540T
C540T
USOTC
RCLFF
RCL Foods (PK)
USOTC
CAIHF
Chia Tai Enterprises (PK)
AMEX
PW
Power REIT
COIN
KRAKGBP
TSXV
SIP
Sniper Resources Ltd.
BIT
UC3WND
Unicredit Bank
NYSE
CNL
Cleco
NYSE
JLL
Jones Lang LaSalle
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有